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'p < 0.05, "p ~ 0.01 (Student's t test L-C vs PI)
fied by the detergent pluronic F-68 and a variety of lipids, significantly re-
duces myocardial reperfusion injury (RI) in animals and humans as shown in
some initial clinical trials. Potential mechanisms for Fluosol include enhanced
O2 delivery to the reperfused tissue and modulation of various neutrophil
(PMNs) functions. Recent studies in dogs and man demonstrate the same
beneficia: effect for treatment of Rl with the detergent component alone,
RheothRx, which is currently undergoing clinical trials. We have shown that
the effect of Fluosol on PM Ns is related to this detergent. However, pro-
longed infusion (48 hrs) of detergent is required to reduce Rl to the same
extent as Fluosol given over only 1 hr. Possible mechanisms for the benefi-
cial effects of Fluosol (02 delivery vs effects on PMNs) were investigated in
a model of regional ischemia utilizing rabbits undergoing 30 mins of circum-
flex occlusion and 48 hrs of reperfusion. Infarct size (area of necrosis, AN)
was determined histologically and expressed as percent of risk region (area
at risk, AR). Animals received Fluosol (30 cc/kg) with or without 02 or saline
over the first 60 mins of reperfusion. AR was similar in all groups. (Mean ±
SEM of AN/AR (%), n ~ 11 for all groups). The treatment with Fluosol with or
without 02 (44 ± 3 and 40 ± 3, respectively) was significantly (p < 0.05) re-
duced compared to control (63 ± 4). Another group received F-I08, a larger
size pluronic detergent found to be 2.5-fold more potent in suppressing PMN
function in vitro compared to F-68, during the first 3 hrs of reperfusion. This
treatment did not alter the infarct size (63 ± 5). RheothRx was found to form
4 nm micelles in solution whereas Fluosol formed particles approximately
100 times larger. Similar sized particles were formed by substituting the per-
fluorocarbons with mineral oil. The in vitro activity of this pluronic/mineral oil
micelle on PMN function was similar to Fluosol. Infusion of these larger oil
micelles was tolerated by rabbits and used in further infarct studies. Con-
clusions; These studies suggest that (1) reduction of RI by Fluosol is not
due to enhanced 02 delivery by the PFCs to reperfused myocardium and (2)
since the Fluosol emulsion markedly reduces the clearance of the detergent
F-68 (tv,: Fluosol ~ 8 hrs vs RheothRx ~ 1.5 hrs). prolonged PMN suppres-
sion rather than potency of suppression is the mechanism whereby Fluosol
ameliorates RI. FluosoJ's clinical efficacy may be enhanced by prolonging its
infusion to ensure an adequate blood level to suppress PMN function be-
yond the time of reperfusion injury. RheothRx's clinical usefulness may be
facilitated by decreasing its renal clearance by delivering larger micelles of
the detergent in order to produce prolonged PMN suppression with a shorter
infusion time.
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Clinical and angiographic data were analysed in 244 pts submitted to a suc-
cessful primary PTCA within 24 hrs of acute MI to determine predictors of
early recovery in LV function. All pts had a LV angiogram before PTCA and at
hospital discharge (HD - mean = 10 days). The end points were: analysis of
arterial patency rate at HD and its relation to ejection fraction (EF) recovery
and in pts with sustained arterial patency (SAPj, which ones exhibit a greater
increase in EF. P values < 0.05 were submitted to multivariate analysis (risk
adjustment).
Variable % Pre EF HD EF GAIN P
Arterial Patency 91 43 ± 9 49± 8 +6.1 ±4% 0.001'
Reocclusion 9 45 ± 8 41 ± 10 -3.4 ± 5%
ONLY PTS WITH SAP:
Anterior MI 52 41 ± 7 47 ± 9 +6.3 ± 4% 002
Inferior MI 48 49 ± 9 52 ± 10 +3.1 ± 2%
Ischemia time < 4 hrs 42 44± 8 53 ± 9 +9.4 ± 5% 0.001*
Ischemia time> 4 hrs 58 44± 9 49± 5 +5.1 ± 2%
Multivessel disease 52 42 ± 9 50 ± 7 +8.1 ± 4% 002
Single vessel disease 48 44± 10 48± 9 +3.9 ± 3%
Baseline EF < 40% 43 33 ± 9 42± 8 +9.6± 5% 0.001'
Baseline EF > 40% 57 51 ± 9 54 ± 5 +3.2 ± 1%
• 1I00CA.
Effects of L-Carnitine on Left Ventricular Function
After Acute Myocardial Infarction. Results of the
CEDIM (Carnitina Ecocardiografia Digitale Infarto
Miocardico) Trial
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Results: 3 months 6 months 12 months
L'l.%-EDV L-C 11.1 ± 30.2 12.7 ± 26.8 191 ± 36.2
PI 18.0 ± 33.0' 19.5 ± 30.6' 28.5 ± 402'
L'l.%-ESV L-C 12.6 ± 41.6 15.1 ± 368 289 ± 51.4
PI 22.5 ± 42.8' 256 ± 42.3" 39.9 ± 55.1'
Sabino Iliceto, Vito Marangelli, Giuseppe Santoro. Luca Bani.
Gaetano D'Ambrosio, Domenico Scrutinio, Paolo Bruzzi, Paul G. Hugenholtz,
Paolo Rizzon, CEDIM Investigators. Institute of Cardiology, Bari, Italy
Limitation of left ventricular (LV) dilatation (LV remodeling) after acute my-
ocardial infarction (AMI) has become an essential therapeutic goal since the
entity of LV dilatation after AMI is now recognized to be the most power-
ful prognostic predictor for clinical outcome. L-Carnitine (L-C) is an essential
compound of cardiac metabolism that favours the optimal utilization of en-
ergetic substrates. Experimental studies have demonstrated that L-C admin-
istration during and after myocardial ischemia restores L-C cardiac depletion
following ischemia and exerts a beneficial effect on LV function. To test the
hypothesis, that timely restoration of adequate intracardiac L-C levels after
AMI could limit LV dilatation on a long-term basis in a clinical setting, a mul-
ticenter, randomized, double-blind, placebo controlled trial was undertaken
(CEOIM trial). 472 pts with first, anterior AMI and high quality entry 20 echo
were enrolled (370/472 pts underwent thrombolysis). Pts were randomized
to placebo (PI) or L-C (6 g/day iv for the first 5 days and 9 g/day orally for the
following 12 months). 20 echo was digitally performed on admission, at 3,
6, 12 months after AMI. 2D echo images were transmitted via modem using
a long-distance network to a Core Laboratory where end-diastolic and end-
systolic volumes (EOV, ESV) were assessed. Baseline clinical and echocar-
diographic characteristics were similar in L-C and PI groups. Percent variation
(L'l. %) of EOV and ESV at 3, 6,12 months from baseline was evaluated in both
PI and L-C groups.
Conclusions; (i) The beneficial effect of lido on infarct size was associated
with a significant reduction in the accumulation of PMNs in the reperfused
rabbit myocardium. (ii) This beneficial effect may occur as a direct inhibitory
effect of lido on PMNs. (iii) This effect of lido on infarct size may also OCCur in
man as human cells respond similarly in vitro to equal doses of lidocaine. (iiii)
Lidocaine may confound the interpretation of other interventions to reduce
infarct size in animals and possibly in man.
1923-21
Congestive heart failure developed in 10 pts (4.2%) on PI vs 4 pts (1.7%) on
L-C. Conclusion; Timely administration of L-C after AM I limits LV dilatation in
the first year after AMI and, therefore, represents a new approach to optimize
LV remodeling after AMI.
Conclusions; Pts with SAP' and anterior Ml, multivessel disease, baseline
EF < 40%' and early reperfusion' are likely to benefit most from primary
PTCA in acute myocardial infarction ('independent variables).
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Local administration of recombinant tissue factor pathway inhibitor (rTF PI).
the physiologic inhibitor of the tissue factor-factor Vila complex that also in-
hibits factor Xa, attenuates necrosis after reperfusion of ischemic ears in rab-
Fluosol Reduces Myocardial Reperfusion Injury by
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Enhancing 02 Delivery
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Fluosol, a complex mixture of 02 carrying perfluorocarbons (PFCs) emu lsi-
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